Abstract
Acute myocardial infarction has become a serious disease that affects the quality of contemporary human survival, and improved efficacy and risk avoidance can be achieved through the upgrading of thrombolytic drugs and precise intervention. This article takes the development of three generations of thrombolytic drugs as the main line, and combs through the development of thrombolytic drugs from the era of urokinase and streptokinase to Alteplase and single-chain urokinase-type fibrinogen activator and their respective advantages and disadvantages. The advantages of three generations of tissue-type fibrinogen kinase derivatives, Reteplase, and tenecteplase, are compared and described in this article.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have